Ovarian cancer: Current and new drug delivery system

The primary cause of death from gynecologic malignancies is ovarian cancer, which makes up 4% of all cancers in women. Approximately 75% of women with early-stage ovarian cancer present with advanced disease at diagnosis because the disease is typically asymptomatic. The disease's stage has a significant impact on survival: Those with early-stage disease have an 80%-90% 5-year survival rate, while those with advanced-stage disease have a 25% survival rate. The diverse group of neoplasms known as ovarian carcinomas is traditionally divided into subgroups according to the type and extent of differentiation. It is becoming clear that each major histological type of ovarian carcinoma has distinctive genetic defects that deregulate particular signaling pathways in the tumor cells, despite the fact that current clinical management of the disease largely ignores this heterogeneity. Furthermore, the molecular pathogenesis of low-grade versus high-grade tumors seems to be largely different within the most common histological types. Many of the morphological characteristics, biological characteristics, and gene-expression patterns of specific ovarian cancer subtypes have been replicated in mouse models of ovarian carcinoma. These models will probably be helpful for researching the biology of ovarian cancer and for preclinical testing of molecularly targeted treatments, which could eventually lead to better clinical outcomes for women with ovarian cancer.